000			01862nam a22002898i 4500
005			20250918151248.0
008			120308s2011 flu b 001 0 eng
020			_a9781439810675 _cRM409.12
039		9	_a201205021144 _bzainol _y03-08-2012 _zyusri
040			_aUKM
090			_aWN415.W714r 2011 9
090			_aWN415 _b.W714r 2011 9
100	1		_aWilliams, Lawrence E.
245	1	0	_aRadiopharmaceuticals : _bintroduction to drug evaluation and dose estimation / _cLawrence E. Williams.
260			_aBoca Raton : _bCRC Press, _c2011.
300			_axxi, 304 p. : _bill. ; _c24 cm.
520			_a'This comprehensive overview details the process of radiopharmaceutical development, from cellular studies to animal experiments to the design and implementation of clinical trials. It examines the relative benefits of various radiopharmaceuticals and provides guidance on dose estimation and agent selection. Utilizing figures of merit for quantitative assessment, it covers standard medical internal radiation dose (MIRD), absorbed dose method for imaging agents, vivo methods for obtaining activity data, errors of activity estimation techniques, phantom-based and patient-based dose estimates and their associated uncertainties, and options available to clinical physicists. Supported by numerous examples from clinical trials, it discusses two and three dimensional estimation processes, including modern hybrid scanners such as SPECT /CT and PET/CT'--Provided by publisher.
650		2	_aRadiopharmaceuticals.
650		2	_aClinical Trials as Topic.
650		2	_aRadiopharmaceuticals _xadministration & dosage.
907			_a.b15263496 _b2021-05-28 _c2019-11-12
942			_c01 _n0 _kWN415.W714r 2011 9
914			_avtls003489997
991			_aFakulti Farmasi, KKL.
998			_ad _b2012-08-03 _cm _da _feng _gflu _y0 _z.b15263496
999			_c510411 _d510411